This week on “The Top Line,” we explore the European biotech investment landscape.
Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
A look at pharma revenue rankings
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
The top money raisers in biotech
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
The most anticipated drug launches of 2024
[Sponsored] Turning information into outcomes with MedThink Communications
[Sponsored] Talking technology and collaboration with Cytiva
Navigating the future of medical AI
Closing the $1 trillion women’s health gap
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast
Bloomberg Surveillance